Invention Grant
- Patent Title: Inhibitors of interleukin-1β converting enzyme
- Patent Title (中): 白细胞介素-1抑制剂 转化酶
-
Application No.: US11655938Application Date: 2007-01-18
-
Publication No.: US07790713B2Publication Date: 2010-09-07
- Inventor: Mark James Batchelor , David Bebbington , Guy W. Bemis , Wolf Herman Fridman , Roger John Gillespie , Julian M. C. Golec , Yong Gu , David J. Lauffer , David J. Livingston , Saroop Singh Matharu , Michael D. Mullican , Mark A. Murcko , Robert Murdoch , Philip Nyce , Andrea L. C. Robidoux , Michael Su , M. Woods Wannamaker , Keith P. Wilson , Robert E. Zelle
- Applicant: Mark James Batchelor , David Bebbington , Guy W. Bemis , Wolf Herman Fridman , Roger John Gillespie , Julian M. C. Golec , Yong Gu , David J. Lauffer , David J. Livingston , Saroop Singh Matharu , Michael D. Mullican , Mark A. Murcko , Robert Murdoch , Philip Nyce , Andrea L. C. Robidoux , Michael Su , M. Woods Wannamaker , Keith P. Wilson , Robert E. Zelle
- Applicant Address: US MA Cambridge
- Assignee: Vertex Pharmaceuticals Incorporated
- Current Assignee: Vertex Pharmaceuticals Incorporated
- Current Assignee Address: US MA Cambridge
- Agency: Ropes & Gray LLP
- Agent James F. Haley, Jr.; Brian M. Gummow
- Main IPC: C07D243/12
- IPC: C07D243/12 ; A61K31/55 ; A61P29/00
Abstract:
The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing-N-acylamino compounds.
Public/Granted literature
- US20080039449A1 Inhibitors of interleukin-1beta converting enzyme Public/Granted day:2008-02-14
Information query
